Novartis CEO joins board of "responsible" AI firm Anthropic
In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.
Newsletters and Deep Dive digital magazine
In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.
Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.
InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition.
Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.
Even modest improvements in early predictive resolution can materially shift portfolio economics.
Editor's Picks
Newsletters and Deep Dive
digital magazine